“Efficacy, Durability, And Retreatment Outcomes Of Risankizumab In Moderate To Severe Plaque Psoriasis: Results From The Phase 3 Immhance Trial”, JOC, vol. 15, no. 1, Dec. 2016, doi: 10.64149/.